Drug Index


Mechanism :

Disopyramide is a Type 1 antiarrhythmic drug. It decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.

Indication :

  • Ventricular arrhythmias

Contraindications :

Contraindicated in the presence of cardiogenic shock, pre-existing second- or third-degree AV block (if no pacemaker is present), congenital Q-T prolongation, or known hypersensitivity to the drug.

Dosing :

Give 6 hourly per oral.
<1 year:
10 to 30 mg/kg/day.
1 to 4 years:
10 to 20 mg/kg/day.
4 to 12 years:
10 to 15 mg/kg/day.
12 to 18 years:
6 to 15 mg/kg/day.

Adverse Effect :

Hypotension, congestive heart failure, anticholinergic effects (urinary retention, urinary urgency, constipation, flatulence, blurred vision, dry eyes), impotence, dry throat, weight gain, anorexia, vomiting, allergic rash, hypokalemia, muscle weakness, chest pain, hypoglycemia, lupus, peripheral neuropathy, sleep disturbances.

Interaction :

Phenytoin may lower plasma levels of disopyramide. Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently. Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations.

Quinidine: Concomitant administration with quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
Erythromycin: Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Oral: 100 mg every 8 hours or 150 mg every 12 hours
10-20Oral: 100 mg every 12 hours
<10Oral: 150 mg every 24 hours (monitor levels)

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

Hepatic impairment causes an increase in the plasma half-life of Disopyramide and a reduced dosage may be required.
02/21/2024 22:33:11 Disopyramide
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0